Researchers found a decreased risk of certain types of ovarian tumors with moderate recreational physical activity, but not others. Physical activity also regulates hormone and growth factor levels, reducing ovarian cancer risk by affecting obesity.
A study led by Daniel W. Cramer found that high blood levels of antibodies against MUC1 protein are associated with lower incidence of ovarian cancer. These events include bone fractures and gynecological surgeries, suggesting a potential link between immune system activation and cancer protection.
Researchers at Yale University have developed a new blood test for ovarian cancer screening using four biomarkers, showing high sensitivity and specificity. The test predicts cancer in patients whose levels of two or more biomarkers fall within a certain warning area.
A study by Vanderbilt University researchers found that inhibiting COX-1 slowed the growth of epithelial ovarian tumors in a mouse model. This breakthrough suggests targeting COX-1 as a novel approach to prevent and treat ovarian cancer.
A study by Fox Chase Cancer Center researchers identified a subset of ovarian cancer patients who respond to Iressa, a targeted therapy. The team found that mutations in the EGFR tyrosine kinase portion of the receptor can make tumors more susceptible to the drug, potentially leading to improved treatment outcomes for some patients.
RAD001 targets mTOR enzyme in high-AKT activity ovarian cancer cells, arresting cell division and reducing angiogenesis. The treatment may be combined with chemotherapy to kill weakened cancer cells.
Researchers found that capsaicin, a compound in red chili pepper, exhibited anticancer activity against pancreatic cancer cells. Phenethyl isothiocyanate (PEITC), a constituent of cruciferous vegetables like broccoli, also showed therapeutic benefits in inhibiting ovarian cancer cell growth.
A clinical trial found that systematic aortic and pelvic lymphadenectomy improved progression-free survival, but not overall survival, in patients with advanced ovarian cancer. The procedure did not significantly increase median overall survival duration.
Researchers discovered that shape-altering genes, known for their role in embryonic development, direct ovarian cancer cells to take on various forms. These unique shapes make each form of ovarian cancer distinct from one another and the surface epithelium.
Women with a family history of breast or ovarian cancer are more likely to receive genetic counseling if they're white. African American women are less aware of genetic testing technology and underestimate their cancer risk. The study found a significant racial disparity in the use of BRCA1/2 testing, which is not explained by socioeco...
USC researchers found that the BRCA1 gene disrupts interactions between different cell types, leading to ovarian cancer. The gene's indirect action may lead to new treatment options by targeting a biochemical mediator.
A study by Yale University reveals that 0.8% of women with non-invasive breast cancer (DCIS) have BRCA1 mutations, while 2.4% have BRCA2 mutations, similar to those found in more advanced breast cancers. Women with these mutations are at higher risk for early detection and may benefit from high-risk screening protocols.
Researchers from USC found evidence that progesterone signaling influences ovarian cancer risk, particularly two haplotypes (4-D and 4-E) that increase risk by almost 3.5-fold in women who carry them. The study's findings suggest that subtle changes in the progesterone receptor gene may decrease its efficiency, leading to ovarian cancer.
Researchers used gene expression profiling to develop a prognostic profile for ovarian cancer, identifying 115 genes that provide important information about prognosis. This technology holds promise for understanding the root causes of ovarian cancer and designing targeted therapies.
Urinary incontinence and abdominal pain are key symptoms of ovarian cancer, with crampy abdominal pain being the most common symptom. The study found that women often ignore or downplay these symptoms, leading to delayed diagnosis.
BRCA1 mutations are found in only 5% of breast and ovarian cancers, but loss-of-function mutations can significantly increase cancer risk. Researchers review preclinical and clinical evidence to determine if BRCA1 function can predict chemotherapy response, highlighting the need for prospective studies.
A large population study has found that most ovarian cancers in families with at least one woman with breast cancer are not related to BRCA1/2 mutations. Instead, other factors may contribute to the increased risk of ovarian cancer in these families.
In a breakthrough procedure, doctors have successfully transplanted a healthy ovary from a patient's body into her upper arm, preserving her fertility. The innovative technique uses brachial vessels to establish blood supply and has shown promising results in maintaining cyclical follicular growth.
Dr. Lancaster's presentation at the IGCS conference used microarray analysis to predict response to platinum-based chemotherapy for advanced stage epithelial ovarian cancers. The study aimed to individualize therapy for patients with advanced ovarian cancer, showcasing Moffitt's expertise in gynecologic cancer research.
IU researchers aim to capitalize on human genome data and powerful bioinformatics approaches to develop better therapies for ovarian and breast cancer patients. The study will focus on genetic and molecular consequences of DNA modifications to improve predictive models.
Research found ovarian cancer rates levelling across Europe, with declining incidence and mortality rates in northern countries, particularly among younger age groups. In contrast, southern and eastern European countries saw increasing cancer incidence and mortality rates.
A new protein, Rab25, has been associated with increased aggressiveness in both breast and ovarian cancers. Low levels of Rab25 protein expression were found to be linked to better clinical outcomes, with patients experiencing higher survival rates when tumors expressed low levels of the protein.
A meta-analysis of RCT data found that patients receiving adjuvant chemotherapy had a lower risk of death and recurrence than those not receiving chemotherapy. Women with optimally staged stage I ovarian cancer may have an excellent prognosis without adjuvant chemotherapy.
A 39-year-old woman gave birth to a healthy baby girl after undergoing orthotopic autotransplantation of cryopreserved ovarian tissue. This procedure bypasses the need for in-vitro fertilization, offering new hope for young cancer patients facing premature ovarian failure.
Fox Chase Cancer Center researchers have identified hypermethylation of BRCA1 and RASSF1A genes as a potential target for detecting ovarian cancer in blood. The study found that 82% of patients with ovarian cancer had hypermethylated genes in their blood DNA, making it a promising diagnostic tool.
In a breakthrough study, researchers found that dendritic cells, a type of immune cell, can be co-opted by tumors to promote angiogenesis and tumor growth. The study suggests a new approach to fighting solid tumors by targeting the interaction between angiogenesis and the immune response.
Researchers identify three biomarkers from serum proteomic analysis that correctly identified 74% of early-stage ovarian cancers, improving detection capabilities. The test combines these markers with CA125 for enhanced accuracy.
Researchers found that ovarian cancer tumors lack response to antiestrogens due to decreased ER beta expression, which can lead to increased cell proliferation and apoptosis. The reintroduction of ER beta in cancer cells induced apoptosis, suggesting its regulatory functions in controlling ovarian cancer growth and motility.
Researchers have identified a potential biomarker for ovarian cancer using a blood test that accurately predicts the presence of the disease in 93% of cases. The study suggests that lysophospholipids, found in high levels in most ovarian cancer patients, may be used to develop an early detection strategy for this devastating disease.
Researchers are collecting blood samples from hundreds of women to validate the novel approach. The test has received worldwide attention due to its potential for early detection and high survival rates. If successful, it could save thousands of lives annually.
A study by Johns Hopkins Medicine found that nearly half of ovarian cancer surgeries in Maryland were performed by low-volume surgeons, those with four or fewer cases per year. High-volume surgeons, who perform more than 10 cases per year, are more likely to accurately assess disease stage and increase survival rates.
The US Preventive Services Task Force recommends against routine ovarian cancer screening due to no evidence that it reduces mortality. In contrast, they support regular eye exams for children under 5 to detect amblyopia and other causes of visual impairment. Early detection can improve visual acuity and prevent long-term harm.
Researchers examined 45 primary ovarian carcinoma samples and found that 40% had decreased or complete loss of Rb2 protein expression. The study suggests Rb2's role in ovarian carcinogenesis and potential clinical applications for detecting and treating cancer.
Researchers at University of Pittsburgh successfully used suspension culture systems to promote follicular growth in rats and mice, showing promise for preserving ovarian fertility after cancer treatment. The study's findings suggest a promising step towards conserving fertility for cancer patients.
A Medical College of Georgia study aims to identify specific protein markers in the blood that indicate how ovarian cancer responds to therapy. By analyzing changes in protein expression over time, researchers hope to develop a better understanding of the disease process and create more effective screening tests.
Researchers discovered structural changes in ovary lining cells and higher levels of Bcl-2 protein in women with ovarian cancer. These findings suggest potential early detection methods for the disease.
Researchers found that COX-2 over-expression promotes loss of basement membrane in ovarian epithelium cells, leading to disorganization and cancer. The study suggests COX-2 inhibitors may prevent cancer development by reducing basement membrane loss.
A breakthrough in fertility preservation allows women to store their ovarian tissue before cancer treatment, which can be transplanted years later to restore reproductive function. The technique shows promise but also raises concerns about safety and effectiveness, prompting calls for further research.
Phenoxodiol, a chemo-sensitizer, has shown encouraging results in treating late-stage ovarian cancer. The study found 25% response rates and synergy with chemotherapy, suggesting potential benefits for patients.
A landmark study provides accurate lifetime risk estimates for BRCA1 and BRCA2 gene mutations, with women carrying the BRCA1 gene facing a 54% risk of ovarian cancer. The study also highlights the negative impact of obesity and lack of exercise on breast cancer development in women with the mutation.
A new biomarker for ovarian and uterine carcinomas has been identified, associated with poor clinical outcome. L1 glycoprotein was found in 46 of 58 ovarian cancers and 20 of 72 uterine cancers, indicating a bad prognostic factor for patient survival.
The Annual Report to the Nation on Cancer statistics shows stabilized cancer rates. A study found carboplatin-paclitaxel is better tolerated in ovarian cancer patients than cisplatin-paclitaxel. Another study linked blood transfusions with HHV-8 seropositivity, while HPV status may predict cervical lesion prognosis
A recent study found that the TGFBR1*6A gene is associated with a 26% increase in cancer risk, particularly for breast, ovarian, and colon cancers. The study's findings suggest that genetic testing and counseling can help identify individuals at high risk and provide targeted prevention strategies.
Researchers have identified new serum biomarkers for ovarian cancer, which may be used in conjunction with existing methods such as CA125 marker and ultrasound to improve diagnosis. These newly discovered markers show promise in detecting the disease at an early stage, leading to better treatment outcomes.
Research highlights the link between high animal fat intake and increased breast cancer risk, as well as the benefits of gynecologic surgeries in reducing ovarian cancer risk. Protein overexpression is also linked to esophageal cancer development, suggesting a potential target for prevention.
Researchers found a slightly increased risk of ovarian cancer in women with endometriosis, with a half-life increase and higher risks for younger women. In contrast, the risk of cervical cancer was reduced by roughly a third. Further investigation is needed to understand the connection between endometriosis and cancer.
Studies on prophylactic surgery for women with BRCA1/2 mutations show a significant reduction in breast and ovarian cancer risk. However, potential biases in study designs, such as confounding by indication and familial-event bias, may lead to underestimation of risk reduction.
A new biomarker, HE4, has been identified as a potential tool for early detection of ovarian cancer. The molecule is secreted into the blood and its presence can be detected in simple clinical tests.
The European Society for Medical Oncology (ESMO) presented a new drug, ET743, which has shown promising results in treating advanced ovarian cancer. In a clinical trial, the drug reduced tumors in 47% of patients, with some experiencing complete responses.
A study of 800 women with relapsing ovarian cancer found that combination chemotherapy showed a modest survival benefit compared to platinum-based chemotherapy alone. Women assigned combination therapy survived for an average of five months more than those given platinum therapy.
Two studies found that paclitaxel-based chemotherapy regimens and mini-transplants can help preserve ovarian function in younger patients. The paclitaxel regimen improved a woman's chance of regaining her ovarian function, while mini-transplants showed better results in preserving ovaries compared to high-dose chemo.
Researchers have discovered a second mechanism by which LPA promotes ovarian tumor growth through increased cyclin D1 protein levels. Additionally, the identification of PEP, a peptide fragment with vasopermeability activity, may help reduce toxicity in cancer immunotherapy. A new study also suggests that p16 inhibitors play a role in ...
A new radiology procedure has been shown to alleviate pain caused by uterine fibroids, with all nine patients experiencing significant symptomatic improvement. The procedure involves blocking blood flow to the affected area using special particles or spheres, resulting in normal menstrual periods and no hormonal changes.
Researchers at Cedars-Sinai Medical Center found that patients with hereditary BRCA-associated ovarian cancer respond better to chemotherapy, leading to improved survival. The study suggests that platinum-based chemotherapy may be more effective for these patients, and this finding may enable physicians to better plan treatment.
Researchers found that ovarian cancer cells produce collagen VI, which remodels their environment to make them more resistant to chemotherapy. This could lead to new therapeutic interventions to overcome chemotherapy resistance and improve survival rates for women with ovarian cancer.
Researchers found that 68% of invasive low-grade ovarian tumors and 61% of precancerous lesions carried one of the three common mutations in BRAF or KRAS. Blocking KRAS-BRAF signaling may provide more effective therapy for these cancers, which generally do not respond well to conventional chemotherapy.
Researchers at Fox Chase Cancer Center developed a transgenic mouse model of epithelial ovarian cancer, allowing scientists to study the disease's progression from early stages. The model has the potential to facilitate advances in early detection and treatment of ovarian cancer.
Researchers at Vanderbilt University Medical Center found that COX-1, not COX-2, is expressed in epithelial ovarian cancer tissue samples. This discovery may lead to the development of new treatments for ovarian cancer by blocking both COX-1 and COX-2.
Researchers used digital SNP analysis to detect ovarian cancer in 87% of early-stage and 95% of late-stage patients, with high total DNA amounts found in most cancer cases. The test holds promise for improved detection in a wide range of cancers.
A new study published in Obstetrics and Gynecology found that aspirin inhibited ovarian tumor cell growth by as much as 68 percent. Combining aspirin with a monoclonal antibody targeting the HER-2/neu protein resulted in an even greater suppression of growth, decreasing cancer cell growth by 84 percent.